For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy .

Full details of the evidence and the committee's discussion are in evidence review A: prognostic factors for progression of non-proliferative diabetic retinopathy.

and findings from a clinical trial focused on non-proliferative diabetic retinopathy. Ocular is utilizing its proprietary bioresorbable hydrogel technology, ELUTYX™, in its ongoing trials ...

Background: This study was performed to assess the prevalence of dry eye syndrome and diabetic retinopathy (DR ... with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate NPDR ...

Diabetic patients were categorised into non-diabetic retinopathy (without diabetic retinopathy), non-proliferative diabetic retinopathy (NPDR), and proliferative diabetic retinopathy (PDR) subgroups ...

in noninferior to anti-VEGF treatment for proliferative diabetic retinopathy (PDR). Additionally, not all DME requires treatment. “If you look at subclinical, non-center involved DME and follow ...

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and severe non-proliferative diabetic retinopathy to proliferative diabetic ...

Faricimab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase II drugs for ...

Tarcocimab tedromer is under clinical development by Kodiak Sciences and currently in Phase III for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase III drugs for ...

The Arogya Aarohan application to assess the risk of oral cancer is just one of the few AI-driven initiatives aimed at detecting diseases like tuberculosis, diabetic retinopathy ... labelled as ...